These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1322 related items for PubMed ID: 8982148

  • 1. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [Abstract] [Full Text] [Related]

  • 3. Minimal doses of hydroxyurea for sickle cell disease.
    Lima CS, Arruda VR, Costa FF, Saad ST.
    Braz J Med Biol Res; 1997 Aug; 30(8):933-40. PubMed ID: 9361721
    [Abstract] [Full Text] [Related]

  • 4. Hydroxyurea and sickle cell anemia: effect on quality of life.
    Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, Koshy M, Barton BA, Bonds DR.
    Health Qual Life Outcomes; 2006 Aug 31; 4():59. PubMed ID: 16942629
    [Abstract] [Full Text] [Related]

  • 5. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.
    JAMA; 2003 Apr 02; 289(13):1645-51. PubMed ID: 12672732
    [Abstract] [Full Text] [Related]

  • 6. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.
    Pediatr Hematol Oncol; 1999 Apr 02; 16(3):221-32. PubMed ID: 10326220
    [Abstract] [Full Text] [Related]

  • 7. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.
    Hemoglobin; 2012 Apr 02; 36(4):323-32. PubMed ID: 22734586
    [Abstract] [Full Text] [Related]

  • 8. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.
    Youssry I, Abdel-Salam A, Ismail R, Bou-Fakhredin R, Mohamed Samy R, Ezz El-Deen F, Taher AT.
    Hemoglobin; 2017 Apr 02; 41(4-6):267-273. PubMed ID: 29251012
    [Abstract] [Full Text] [Related]

  • 9. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
    Ballas SK, McCarthy WF, Guo N, Brugnara C, Kling G, Bauserman RL, Waclawiw MA.
    Hemoglobin; 2010 Apr 02; 34(5):424-9. PubMed ID: 20854115
    [Abstract] [Full Text] [Related]

  • 10. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
    Saleh AW, Hillen HF, Duits AJ.
    Acta Haematol; 1999 Apr 02; 102(1):31-7. PubMed ID: 10473885
    [Abstract] [Full Text] [Related]

  • 11. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
    Borba R, Lima CS, Grotto HZ.
    J Clin Lab Anal; 2003 Apr 02; 17(2):66-72. PubMed ID: 12640630
    [Abstract] [Full Text] [Related]

  • 12. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.
    de Montalembert M, Belloy M, Bernaudin F, Gouraud F, Capdeville R, Mardini R, Philippe N, Jais JP, Bardakdjian J, Ducrocq R, Maier-Redelsperger M, Elion J, Labie D, Girot R.
    J Pediatr Hematol Oncol; 1997 Apr 02; 19(4):313-8. PubMed ID: 9256830
    [Abstract] [Full Text] [Related]

  • 13. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR.
    N Engl J Med; 1995 May 18; 332(20):1317-22. PubMed ID: 7715639
    [Abstract] [Full Text] [Related]

  • 14. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
    Bachir D, Hulin A, Huet E, Habibi A, Nzouakou R, El Mahrab M, Astier A, Galacteros F.
    Hemoglobin; 2007 May 18; 31(4):417-25. PubMed ID: 17994375
    [Abstract] [Full Text] [Related]

  • 15. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Nevitt SJ, Jones AP, Howard J.
    Cochrane Database Syst Rev; 2017 Apr 20; 4(4):CD002202. PubMed ID: 28426137
    [Abstract] [Full Text] [Related]

  • 16. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R, Hsieh MM, Zhao X, Calvaruso G, Rigano P, Renda D, Tisdale JF, Maggio A.
    Int J Mol Sci; 2018 Feb 28; 19(3):. PubMed ID: 29495591
    [Abstract] [Full Text] [Related]

  • 17. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.
    Blood; 1999 Sep 01; 94(5):1550-4. PubMed ID: 10477679
    [Abstract] [Full Text] [Related]

  • 18. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
    Haynes J, Obiako B, Hester RB, Baliga BS, Stevens T.
    Am J Physiol Heart Circ Physiol; 2008 Jan 01; 294(1):H379-85. PubMed ID: 17993595
    [Abstract] [Full Text] [Related]

  • 19. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.
    J Pediatr; 1996 Jun 01; 128(6):820-8. PubMed ID: 8648542
    [Abstract] [Full Text] [Related]

  • 20. Sickle cell anemia with systemic lupus erythematosus: response to hydroxyurea therapy.
    Shetty AK, Kumar SR, Gedalia A, Warrier RP.
    J Pediatr Hematol Oncol; 1998 Jun 01; 20(4):335-7. PubMed ID: 9703008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.